UCUlrich Costabel

Ulrich Costabel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ulrich Costabel has a total of 538 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies

    by Jürgen Behr, Steven D. Nathan, Ulrich Costabel, Carlo Albera, Wim A. Wuyts, Marilyn K. Glassberg, Harold Haller, Giuseppe Alvaro, Frank Gilberg, Katerina Samara, et al.

    Introduction In the European Union (EU), the indication for the antifibrotic pirfenidone prior to April 2023 did not include patients with advanced idiopathic pulmonary fibrosis (IPF). This analysis compared the efficacy and safety of pirfenidone in advanced IPF versus non-advanced IPF. Methods Data were included from the following studies of pirfenidone: ASCEND (NCT01366209); CAPACITY (004 [NCT00287716] and 006 [NCT00287729]); RECAP (NCT00662038; advanced IPF defined as percent predicted forced vital capacity [%FVC] < 50% and/or percent predicted carbon monoxide diffusing capacity [%DLco] < 35% at baseline); PASSPORT (NCT02699879; advanced IPF defined as baseline %FVC < 50%); and SP-IPF (NCT02951429; patients with advanced IPF [defined as %DLco ≤ 40% at screening] at risk of group 3 pulmonary hypertension). Results In the pooled ASCEND/CAPACITY studies, the annual mean rate of FVC decline from baseline to Week 52 was significantly lower for pirfenidone versus placebo in advanced (p = 0.0035) and non-advanced IPF (p = 0.0001). Rate of all-cause mortality over 52 weeks was numerically lower for pirfenidone versus placebo in advanced and non-advanced IPF. In RECAP, the mean annual rate of FVC decline from baseline to Week 180 of pirfenidone treatment was similar in patients with advanced (− 141.5 mL) and non-advanced IPF (− 153.5 mL). In SP-IPF, the mean annual rate of FVC decline and rate of all-cause mortality from baseline to Week 52 in patients treated with placebo + pirfenidone were − 93.0 mL and 20.2%, respectively. No new safety signals were identified, and the safety profile of pirfenidone in patients with advanced IPF was generally consistent with that of non-advanced IPF. Conclusions These results highlight the benefit of pirfenidone treatment in patients with advanced and non-advanced IPF. As such, the indication for pirfenidone in the EU has now been updated to include the treatment of adult patients with advanced IPF. Trial Registrations ASCEND (NCT01366209), CAPACITY 004 (NCT00287716), CAPACITY 006 (NCT00287729), RECAP (NCT00662038), PASSPORT (NCT02699879), and SP-IPF (NCT02951429).


  • Transbronchial cryobiopsy: the right procedure for the right patient in the right place at the right time

    by Jeffrey L. Myers, Ulrich Costabel

    This editorial assesses the impact of newly published ERS guidelines for use of transbronchial cryobiopsy for diagnosis of interstitial lung disease, including future areas of research likely to facilitate ongoing global adoptionhttps://bit.ly/3LAy1n8

  • Open Access

    GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial

    by Irina R. Strambu, Christian A. Seemayer, Liesbeth M.-C. A. Fagard, Paul A. Ford, Tom A. K. Van der Aa, Angela A. de Haas-Amatsaleh, Vikas Modgill, Eva Santermans, Eric N. Sondag, Eric G. Helmer, et al.

    Background: GLPG1205 is a selective functional antagonist of G-protein-coupled receptor 84, which plays an important role in fibrotic processes. This study assessed the efficacy, safety and tolerability of GLPG1205 for treatment of idiopathic pulmonary fibrosis (IPF).Methods: PINTA (ClinicalTrials.gov:NCT03725852) was a phase 2, randomised, double-blind, placebo-controlled, proof-of-concept trial. Patients with IPF were randomised 2:1 to once-daily oral GLPG1205 100 mg or placebo for 26 weeks and stratified to receive GLPG1205 alone or with local standard of care (nintedanib or pirfenidone). The primary end-point was change from baseline in forced vital capacity (FVC); other end-points were safety and tolerability, and lung volumes measured by imaging (high-resolution computed tomography). The study was not powered for statistical significance.Results: In total, 68 patients received study medication. Least squares mean change from baseline in FVC at week 26 was −33.68 (95% CI −112.0–44.68) mL with GLPG1205 and −76.00 (95% CI −170.7–18.71) mL with placebo (least squares mean difference 42.33 (95% CI −81.84–166.5) mL; p=0.50). Lung volumes by imaging declined −58.30versus−262.72 mL (whole lung) and −33.68versus−135.48 mL (lower lobes) with GLPG1205versusplacebo, respectively. Treatment with GLPG1205versusplacebo resulted in higher proportions of serious and severe treatment-emergent adverse events and treatment-emergent discontinuations, most apparent with nintedanib.Conclusions: Treatment with GLPG1205 did not result in a significant difference in FVC declineversusplacebo. GLPG1205 demonstrated a poorer safety and tolerability profile than placebo.


  • Open Access

    COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study

    by Spyros A. Papiris, Ilaria Campo, Francesca Mariani, Maria Kallieri, Lykourgos Kolilekas, Andriana I Papaioannou, Efsun Gonca Chousein, Erdogan Cetinkaya, Francesco Bonella, Raphael Borie, et al.


  • Open Access

    Double Lung Transplantation for Idiopathic Pulmonary Fibrosis in a Patient with a History of Liver Transplantation and Prolonged Journey for Disease-Specific Antifibrotic Therapy

    by Sebastian Majewski, Maria Królikowska, Ulrich Costabel, Wojciech J. Piotrowski, Marek Ochman

    Idiopathic pulmonary fibrosis (IPF) is characterized by uncontrolled progressive lung fibrosis with a median survival of 3 to 5 years. Although currently available pharmacotherapy cannot cure the disease, antifibrotics including pirfenidone and nintedanib were shown to slow disease progression and improve survival in IPF. Nevertheless, there is a knowledge gap on the safety of antifibrotics in patients after liver transplantation receiving concomitant immunosuppressive therapy. This case report of a 68-year-old male patient with IPF illustrates how a complex medical history has led to diagnostic and therapeutic challenges considerably affecting clinical decisions and impacting the patient’s journey. The increasing severity of lung function impairment due to the progressive natural history of IPF ultimately led to severe respiratory failure. Double lung transplantation (LTx) was performed as the only therapeutic option in end-stage disease with the potential to improve quality of life and survival. To the best of our knowledge, this is the first case report describing the feasibility and safety of antifibrotic therapy with pirfenidone for IPF in a 68-year-old patient with a history of liver transplantation receiving concomitant immunosuppressive therapy with tacrolimus who underwent successful double lung transplantation when alternative medical interventions had been exhausted.


  • Open Access

    COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study

    by Spyros A. Papiris, Ilaria Campo, Francesca Mariani, Maria Kallieri, Lykourgos Kolilekas, Andriana I. Papaioannou, Efsun Gonca Chousein, Erdogan Cetinkaya, Francesco Bonella, Raphael Borie, et al.


  • Open Access

    CMLD-2 Attenuates Myofibroblast Activation and Bleomycin-Induced Pulmonary Fibrosis in Mice through Antagonizing ELAVL1-Mediated Osteopontin mRNA Stabilization

    by Guo Qiongya, Ren Hongyan, Li Meng, Liu Lifan, Li Wenting, Zhang Jingjing, Wang Xiaoli, Hu Yiping, Zang Kaixuan, An Yunxia, et al.

    Background: Fibroblast-myofibroblasts transition (FMT) is one of the hallmark cellular processes in pulmonary fibrosis. This study is to investigate the effects of CMLD-2 in FMT and pulmonary fibrosis, which antagonizes HuR, a supposedly key regulatory RNA binding protein (RBP). Methods: HuR or other deferentially expressed RBPs during TGF-β1-induced FMT were analyzed by transcriptomic methods, and further validated in vitro or in fibrotic lung specimens. The effects of HuR overexpression, down-regulation or inhibition by an antagonist CMLD-2 were analyzed in FMT or bleomycin-induced experimental lung fibrosis. HuR-targeting RNA and their interactions were analyzed by CLIP-seq. Results: HuR, hnRNPA1, hnRNPE1, TIA1 and TFRC were significantly up-regulated, while ESRP1, ESRP2 and TTP were significantly down-regulated. Cytoplasmic expression of HuR was activated in IPF lung tissue and rat lungs of bleomycin-induced fibrosis. HuR overexpression induced α-SMA and collagen I expression, increased the proliferation and migration capacities of fibroblasts with or without the stimulation of TGF-β1. HuR knockdown by shRNA inhibited the proliferation, transition, collagen production and migration properties in fibroblasts or in TGF-β1-stimulated myofibroblasts. Combinative analysis of RNA-seq and CLIP-seq data revealed major HuR binding motifs and several HuR-bound, differentially expressed mRNAs in FMT, specifically SPP1 mRNA encoding osteopontin. HuR-mediated SPP1 mRNA stabilization was further validated by RIP-PCR and half-life analysis using SPP1 mutant transcripts. Inhibiting HuR using CMLD-2 attenuated SPP1/osteopontin expression, TGF-β1-induced FMT in vitro and bleomycin-induced pulmonary fibrosis in mice. Nuclear-cytoplasmic shuttle of HuR was activated in TGF-β1-induced FMT, which was inhibited by p38MAPK (SB203580) or PKC (Go-6976) inhibition, but not associated with phosphorylation of HuR. Conclusions: Fibroblast-myofibroblast transition is activated by HuR-SPP1 mRNA interactions, and CMLD-2 is potentiated to be a therapeutic agent targeting HuR for fibroblast-myofibroblast transition and pulmonary fibrosis.

  • Sprachliche Validierung des Fibrose-Fragebogens zur Erfassung der Lebensqualität bei Patienten mit idiopathischer Lungenfibrose und idiopathischer nichtspezifischer interstitieller Pneumonie

    by D. Kirsten, U. de Vries, U. Costabel, D. Koschel, F. Bonella, A. Günther, J. Behr, M. Claussen, S. Schwarz, A. Prasse, et al.

    Idiopathische interstitielle Pneumonien sind mit einer deutlichen Minderung der Lebensqualität (LQ) assoziiert. Es existiert in Deutschland lediglich der Lebensqualitätsfragebogen für Patienten mit interstitiellen Lungenerkrankungen (K-BILD; [1]) und eine deutsche Validierung von Kreuter et al. [2] Dieser Fragebogen ist jedoch in der präzisen Erfassung der Lebensqualität (LQ) für Fibrosepatienten eingeschränkt. Daher wurde ein Fragebogen zur Lebensqualität von Patienten mit idiopathischer Lungenfibrose und nicht-spezifischer interstitieller Pneumonie (Fibrose-Fragebogen, FFB) entwickelt und sprachlich validiert. Methode Die linguistische Validierung des FFB erfolgte in einem mehrstufigen Prozess durch enge Zusammenarbeit der Entwickler des Fragebogens mit bilingualen, professionellen Übersetzern durch Hin- und Rückübersetzung, um eine deutsche und englische Version zu erstellen. Ein Vergleich mit dem St. Georges Respiratory Questionnaire (SGRQ) wurde durchgeführt. Ergebnisse Es wurden eine deutsche und eine englische Version des FFB linguistisch validiert. Die Fragen umfassen 5 Skalen und 23 Items mit Aussagen zur Befindlichkeit, Beeinträchtigung und Fragen zu Symptomen wie Atemnot und Husten sowie eine visuelle Analog-Skala zum allgemeinen Gesundheitszustand. Schlussfolgerung Die deutsche und die englische Version des FFB erlauben den klinischen und wissenschaftlichen Einsatz bei Patienten mit progressiver Lungenfibrose wie der idiopathischen Lungenfibrose (IPF) und der idiopathischen nicht-spezifischen Lungenfibrose (iNSIP), um die Lebensqualität zuverlässig bestimmen zu können. Im Verlauf der Erkrankung kann der Einsatz dieses Fragebogens hilfreich sein. Health status and quality of life are impaired in patients with idiopathic pulmonary fibrosis (IPF) and idiopathic non-specific interstitial fibrosis (iNSIP). In Germany exists only the K-BILD questionnaire for patients with ILD [1] in a professional translation by Kreuter et al. [2] This questionnaire focuses on the main problems in patients with progressive lung fibrosis in a limited manner. Therefore a new quality of life questionnaire for patients with idiopathic pulmonary fibrosis was developed and linguistically validated. Methods The linguistic validation of our questionnaire was carried out in a multistage process in collaboration with the developer of the questionnaire and bilingual, professional translators. Review by the developers and back translations as well as clinical assessment by IPF- and iNSIP-patients ensured that the translated questionnaire reflected the intention of the original English version of our questionnaire. Cross-validation was carried out with the St. Georges Respiratory Questionnaire (SGRQ). Results The new questionnaire concerning the health status was composed in English and German language. The questions cover five scales (sensitivity, selectivity and symptoms like breathlessness and cough and a visual analog scale on general health status) with 23 items. Conclusions The results show that the FFB maps the special needs of the patients with IPF and iNSIP well and can support clinical and scientific questions and can be helpful in monitoring the clinical course. * Zum Gedenken an Herrn Prof. Dr. Franz Petermann, Bremen. Er hat die Arbeit an diesem Fragebogen bis zu seinem frühen Tod im August 2019 maßgeblich beeinflusst. Received: 01 December 2020 Accepted: 06 December 2020 Publication Date: 24 August 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey

    by Manuela Funke-Chambour, Carlo Albera, Elisabeth Bendstrup, Ulrich Costabel, Jan C. Grutters, Sergio Harari, Kerri A. Johannson, Michael Kreuter, Irina Strambu, Carlo Vancheri, et al.


  • Open Access

    Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis

    by Toby M. Maher, Ulrich Costabel, Marilyn K. Glassberg, Yasuhiro Kondoh, Takashi Ogura, Mary Beth Scholand, David Kardatzke, Monet Howard, Julie Olsson, Margaret Neighbors, et al.

    This phase 2, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of lebrikizumab, an interleukin (IL)-13 monoclonal antibody, alone or with background pirfenidone therapy, in patients with idiopathic pulmonary fibrosis (IPF).Patients with IPF aged ≥40 years with forced vital capacity (FVC) of 40%–100% predicted and diffusing capacity for carbon monoxide of 25%–90% predicted and who were treatment-naïve (cohort A) or receiving pirfenidone (2403 mg·day−1; cohort B) were randomised 1:1 to receive lebrikizumab 250 mg or placebo subcutaneously every 4 weeks. The primary endpoint was annualised rate of FVC % predicted decline over 52 weeks.In cohort A, 154 patients were randomised to receive lebrikizumab (n=78) or placebo (n=76). In cohort B, 351 patients receiving pirfenidone were randomised to receive lebrikizumab (n=174) or placebo (n=177). Baseline demographics were balanced across treatment arms in both cohorts. The primary endpoint (annualised rate of FVC % predicted decline) was not met in cohort A (lebrikizumabversusplacebo, −5.2%versus−6.2%; p=0.456) or cohort B (lebrikizumabversusplacebo, −5.5%versus−6.0%; p=0.557). In cohort B, a non-statistically significant imbalance in mortality favouring combination therapy was observed (hazard ratio 0.42 (95% CI 0.17–1.04)). Pharmacodynamic biomarkers indicated lebrikizumab activity. The safety profile was consistent with that in previous studies of lebrikizumab and pirfenidone as monotherapies.Lebrikizumab alone or with pirfenidone was not associated with reduced FVC % predicted decline over 52 weeks despite evidence of pharmacodynamic activity. Lebrikizumab was well tolerated with a favourable safety profile. These findings suggest that blocking IL-13 may not be sufficient to achieve a lung function benefit in patients with IPF.